[go: up one dir, main page]

GT200900142A - Combinacion de los inhibidores iap y flt3 inhibidores - Google Patents

Combinacion de los inhibidores iap y flt3 inhibidores

Info

Publication number
GT200900142A
GT200900142A GT200900142A GT200900142A GT200900142A GT 200900142 A GT200900142 A GT 200900142A GT 200900142 A GT200900142 A GT 200900142A GT 200900142 A GT200900142 A GT 200900142A GT 200900142 A GT200900142 A GT 200900142A
Authority
GT
Guatemala
Prior art keywords
combination
inhibitors
iap
flt3
active agents
Prior art date
Application number
GT200900142A
Other languages
English (en)
Inventor
Griffin James Douglas
Zawel Leigh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900142A publication Critical patent/GT200900142A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMBINACIONES DE INHIBIDORES DE IAP E INHIBIDORES DE FLT3, A COMPOSICIONES FARMACOLÓGICAS QUE COMPRENDEN ESTA COMBINACIÓN, LOS CUALES COMPRENDEN LA COMBINACIÓN DE UN COMPUESTO QUE INHIBE EL ENLACE DEL SEGUNDO ACTIVADOR DERIVADO DE MITOCONDRIA DE LA PROTEÍNA DE CASPASA (SMAC) AL INHIBIDOR DE APOPTOSIS (INHIBIDOR DE IAP) POR LO QUE SON DE UTILIDAD EN CUADROS DE LEUCEMIA MIELOIDE AGUDA.
GT200900142A 2006-11-28 2009-05-27 Combinacion de los inhibidores iap y flt3 inhibidores GT200900142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US89108807P 2007-02-22 2007-02-22

Publications (1)

Publication Number Publication Date
GT200900142A true GT200900142A (es) 2010-06-24

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900142A GT200900142A (es) 2006-11-28 2009-05-27 Combinacion de los inhibidores iap y flt3 inhibidores

Country Status (20)

Country Link
US (1) US8492429B2 (es)
EP (1) EP2089024B1 (es)
JP (1) JP5394249B2 (es)
KR (1) KR20090087094A (es)
AT (1) ATE509629T1 (es)
AU (1) AU2007325280B2 (es)
BR (1) BRPI0719543A2 (es)
CA (1) CA2670498A1 (es)
CO (1) CO6210722A2 (es)
EC (1) ECSP099472A (es)
GT (1) GT200900142A (es)
IL (1) IL198551A0 (es)
MA (1) MA30966B1 (es)
MX (1) MX2009005621A (es)
NO (1) NO20092417L (es)
PL (1) PL2089024T3 (es)
PT (1) PT2089024E (es)
RU (1) RU2456983C2 (es)
TN (1) TN2009000206A1 (es)
WO (1) WO2008067280A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
CA2564872C (en) 2005-10-25 2010-12-21 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CA2724720A1 (en) * 2008-05-16 2009-11-19 Novartis Ag Immunomodulation by iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
WO2013049350A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
EP3928780A4 (en) 2019-02-22 2022-12-07 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN FLT3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
PH12021551985A1 (en) 2019-02-22 2022-08-22 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
CN101340947B (zh) * 2005-12-20 2012-09-05 诺瓦提斯公司 Iap-抑制剂和紫杉烷7的组合
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
BRPI0719543A2 (pt) 2014-02-25
MX2009005621A (es) 2009-06-12
WO2008067280A2 (en) 2008-06-05
RU2009124590A (ru) 2011-01-10
US8492429B2 (en) 2013-07-23
NO20092417L (no) 2009-08-25
WO2008067280A3 (en) 2008-08-07
IL198551A0 (en) 2010-02-17
CO6210722A2 (es) 2010-10-20
JP5394249B2 (ja) 2014-01-22
EP2089024A2 (en) 2009-08-19
AU2007325280A1 (en) 2008-06-05
RU2456983C2 (ru) 2012-07-27
TN2009000206A1 (en) 2010-10-18
JP2010511059A (ja) 2010-04-08
PL2089024T3 (pl) 2011-10-31
KR20090087094A (ko) 2009-08-14
AU2007325280B2 (en) 2011-03-10
MA30966B1 (fr) 2009-12-01
ATE509629T1 (de) 2011-06-15
PT2089024E (pt) 2011-08-31
ECSP099472A (es) 2009-10-30
EP2089024B1 (en) 2011-05-18
CA2670498A1 (en) 2008-06-05
US20100056467A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
GT200900142A (es) Combinacion de los inhibidores iap y flt3 inhibidores
MX2009006877A (es) Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
ZA200701629B (en) Gyrase inhibitors and uses thereof
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
NO20091495L (no) Pyrazolopyrimidinderivat
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
SG155939A1 (en) Phosphoindoles as hiv inhibitors
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
EA200900552A1 (ru) Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
PA8593701A1 (es) [4-(3-aminometilfenil)piperidin-1-il]-[5-(2-fluorofenil-etinil)furan-2-il]-metanoma como inhibidor de triptasa de mastocitos
MX2009001384A (es) Inhibidor de aminoisoquinolina de trombina con biodisponibilidad mejorada.
UA88325C2 (en) Phosphoindoles as hiv inhibitors
AU2016219620A1 (en) Compositions and methods useful for treatment of respiratory illness
TW200605878A (en) A pharmaceutical, which can be used for treating and/or preventing ischemia/reperfusion injury